Automation a Path to Lower Cell Therapy Costs
Australian developer Currus Bio predicts that automating the production of its candidate cancer cell therapy, CUR-001, using the Cocoon platform will reduce costs and enhance its ability to scale production as the product moves through trials. The post Automation a Path to Lower Cell Therapy Costs appeared first on GEN - Genetic Engineering and Biotechnology News .
Australian biotech Currus Biologics has automated manufacturing of its cell therapy CUR-001, aiming to cut costs. CEO Sam Cobb explained the move to GEN, describing how the company transferred the CUR-001 process to an automated platform called Cocoon. This optimization focused on reducing viral vector usage, cell densities, and starting materials, resulting in lower manufacturing costs without altering the therapy's biology.
CUR-001 will be produced by Melbourne's Cell Therapies (CTPL) for upcoming Phase I trials. Automation advantages include modular capacity expansion and improved consistency and reproducibility. While fully autonomous manufacturing may be challenging, automation can still improve efficiency in cell therapy production.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
